Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

H. Einstein, Mark; Baron, Mira; J. Levin, Myron; Chatterjee, Archana; Fox, Bradley; Scholar, Sofia; B. Rosen, Jeffrey; Chakhtoura, Nahida; Meric, Dorothée; Dessy, Francis; Datta, Sanjoy; Descamps, Dominique; Dubin, Gary

doi:10.4161/hv.7.12.18281

Public

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

Published in Human Vaccines • Dec 1, 2011

Authors:

Mark H. Einstein

Mira Baron

Myron J. Levin

Abstract

In this observer-blind study (NCT00423046), women (N=1,106), stratified by age (18-26, 27-35, 36-45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vaccine (Gardasil® Merck & Co., Inc., Months 0, 2, 6). Month 7...

Subject

Medicine

Immunogenicity

Gardasil

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!